Century Therapeutics, Inc.
IPSC
$1.92
-$0.01-0.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 14.56% | -13.15% | |||
| Gross Profit | -14.56% | 13.15% | |||
| SG&A Expenses | -7.99% | 42.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.13% | -0.27% | |||
| Operating Income | -7.13% | 0.27% | |||
| Income Before Tax | -59.62% | -12.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -59.62% | -12.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -59.62% | -12.90% | |||
| EBIT | -7.13% | 0.27% | |||
| EBITDA | -9.81% | -2.17% | |||
| EPS Basic | -50.04% | 49.04% | |||
| Normalized Basic EPS | -1.58% | 56.18% | |||
| EPS Diluted | -51.92% | 49.04% | |||
| Normalized Diluted EPS | -1.58% | 56.18% | |||
| Average Basic Shares Outstanding | 6.36% | 121.65% | |||
| Average Diluted Shares Outstanding | 6.36% | 121.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||